Sandoz Generics Claims Survive, Despite Post-Mensing Trend

News | 26 January 2013

Law360, New York (January 25, 2013, 5:38 PM ET) -- An Ohio federal judge ruled Friday that design defect claims brought against Sandoz Inc. by a man allegedly blinded by its generic arrhythmia drug are not preempted by federal law, putting him at odds ...

Click on the link to read the full article at Law360 (subscription)
(This link will open in a new window)